Posted by Michael Wonder on 14 Sep 2016
TGA approves Taltz
14 September 2016 - The TGA has approved Eli Lilly's Taltz (ixekizumab).
The TGA approved ixekizumab on 6 September 2016 for the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
